{"schema_version":"secwatch.filing_event.v1","accession":"0001551152-22-000038","form_type":"8-K","ticker":"ABBV","cik":"0001551152","company_name":"AbbVie Inc.","filed_at":"2022-10-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.111273+00:00","generated_at":"2026-06-22T22:37:21.678113+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"AbbVie Q3 adj. EPS $3.66 (+29.3%) on revenue $14.8B; raises 2023 dividend 5%","bullets":["GAAP diluted EPS $2.21 (+24.2%); adjusted diluted EPS $3.66 (+29.3%), includes $0.02 IPR&D hit.","Total net revenues $14.812B (+3.3% reported, +5.4% operational). Immunology $7.651B (+14.6%).","U.S. Humira $4.956B (+7.4%); international Humira $603M (-25.9%) due to biosimilars; Skyrizi $1.397B, Rinvoq $695M.","Hematologic oncology $1.650B (-11.7%) with Imbruvica $1.135B (-17.4%); Neuroscience $1.672B (+6.7%), Aesthetics $1.301B (+4.0%).","Narrows FY2022 adj. EPS guidance to $13.84-$13.88 (from $13.76-$13.96); announces 5% dividend increase starting Feb 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001551152-22-000038","json":"https://secwatch.observer/filing/0001551152-22-000038.json","markdown":"https://secwatch.observer/filing/0001551152-22-000038.md","text":"https://secwatch.observer/filing/0001551152-22-000038.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1551152/000155115222000038/0001551152-22-000038-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1551152/000155115222000038/abbv-20221028.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T22:37:21.678113+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"eeed642950ff487390009b08d4bd30b8623197e3","claim":"AbbVie Inc. reported the third quarter ended September 30, 2022 results: revenue $14.812 Billion, EPS $3.66. Guidance reaffirmed.","evidence_excerpt":"• Reports Third-Quarter Diluted EPS of $2.21 on a GAAP Basis, an Increase of 24.2 Percent; Adjusted Diluted EPS of $3.66, an Increase of 29.3 Percent; These Results Include an Unfavorable Impact of $0.02 Per Share related to Acquired IPR&D and Milestones Expense 1 • Delivers Third-Quarter Net Revenues of $14.812 Billion, an Increase of 3.3 Percent on a Reported Basis and 5.4 Percent Operationally","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115222000038/0001551152-22-000038-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Revenue","value":"$14.812 Billion"},{"label":"EPS","value":"$3.66"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}